Keryx appoints interim chairman and CEO
This article was originally published in Scrip
Keryx Biopharmaceuticals (US) has named Michael Tarnok interim chairman and chief executive officer; he succeeds Michael Weiss. Mr Tarnok spent the majority of his career at Pfizer, which he joined in 1989; from 2000-07, he served as senior vice-president of finance in the company's US pharmaceuticals division. Mr Tarnok has served on Keryx's board of directors since September 2007.